59 results about "Cardiac hypertrophy" patented technology

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

The invention provides a heart-targeted nano-liposome delivery carrier, a circular RNA (Ribonucleic Acid) medicine for treating cardiovascular diseases as well as a preparation method and application of the circular RNA medicine, and belongs to the technical field of biomedicine. The heart-targeted nano-liposome delivery carrier comprises saccular nano-liposome particles and heart-targeted peptide CMP (chemical mechanical polishing) modified on the surfaces of the nano-liposome particles, the amino acid sequence of the heart targeting peptide CMP is shown as SEQ ID NO: 6. The heart-targeted nano-liposome delivery carrier has a good heart-targeted effect, and the nano-liposome delivery carrier is used as a delivery tool to accurately deliver a circular RNA drug to a heart part, so that the effect of treating cardiovascular diseases (such as cardiac hypertrophy) is greatly improved; a new treatment mode is provided for clinical treatment of cardiovascular diseases, and the purpose of efficiently preventing and treating heart diseases is achieved.

The health-preserving conditioning tea is prepared from the following raw materials in parts by weight: 3 to 8g of earthworms, 2 to 9g of flos carthami, 4 to 7g of ground beetles, 5 to 10g of leeches, 1.5 to 6g of radix aucklandiae, 3 to 8g of herba verbenae, 2 to 5g of gadflies, 3 to 7g of arisaema cum bile, 6 to 10g of radix salviae miltiorrhizae, 4 to 8g of radix paeoniae rubra, 2 to 6g of bombyx batryticatus, 1.5 to 5g of scorpions and 4 to 9g of folium ginkgo. The conditioning tea has the beneficial effects that the conditioning tea not only can replace traditional western medicines and avoid drug resistance and side effects, but also is convenient to carry and take after being bagged, can relieve and reduce the symptoms of cardiovascular and cerebrovascular plaques, namely blockage, during long-term taking according to the treatment course, can prevent cardiovascular and cerebrovascular diseases, activate blood and promote menstruation, and can be used for treating cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition has the effects of tonifying qi, preserving health, reducing blood fat and blood pressure, and also can be used for treating diseases such as chest distress, chest pain, cardiac hypertrophy, mitral valve and tricuspid valve regurgitation, myocardial ischemia and the like.

The invention provides application of isoflurane in preparation of a medicine for preventing and / or treating sympathetic nerve excitation mediated myocardial fibrosis, and belongs to the field of biological medicine. Researches show that after inhalation treatment with the isoflurane, the effect of improving myocardial fibrosis caused by beta-AR excessive activation can be achieved, the development process of cardiac hypertrophy and ventricular enlargement caused by beta-AR excessive activation is delayed, and therefore the isoflurane has a protective effect on the cardiac function. Therefore, the isoflurane can be used for preparing the medicine for preventing and / or treating the sympathetic nerve excitation-mediated myocardial fibrosis, and has a good application prospect.

The present application relates to a PROTAC construction based on E3 ubiquitin ligase ZER1 and target protein DVL2 and its application in heart failure treatment. In particular, the present application provides a proteolysis targeting chimera (PROTAC) complex comprising an E3 ubiquitin ligase binding ligand moiety and a target protein binding ligand moiety connected by a linker, wherein the E3 ubiquitin ligase binding ligand is a ZER1 binding ligand, and the target protein binding ligand is a DVL2 binding ligand. The PROTAC molecule in the present application targets DVL2 ubiquitination degradation by recruiting E3 ubiquitin ligase ZER1 to regulate the CaMKII / HDAC4 / MEF2C signaling axis, thereby reducing pathological cardiac hypertrophy and intervening the progression of heart failure, and providing a new therapeutic target for treating cardiac hypertrophy and heart failure caused by pressure overload.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.

The present application discloses a complete nutritional feline food composition comprising EPA / DHA and carbohydrates. These complete nutritional feline food compositions can be used in dry or wet food compositions. The composition can be used to prevent and / or treat cardiac hypertrophy in felines, such as cats.

The invention relates to the technical field of biological medicine, in particular to application of Rab26 protein in preparation of medicine for preventing or treating cardiac hypertrophy. When the expression level of the Rab26 gene is low (less Rab26 protein is generated), the cardiac muscle cell hypertrophy degree is obviously increased; when the Rab26 gene is over-expressed (more Rab26 protein is generated), the cardiac muscle cell hypertrophy degree is obviously reduced. Therefore, the Rab26 protein is used for preparing the medicine for preventing or treating cardiac hypertrophy.

The invention discloses a PARP1 inhibitor with methyl-1 'H-spiro [piperidine-4, 2'-quinazoline]-4 '(3' H)-ketone as a mother nucleus and a preparation method and application of the PARP1 inhibitor, a main compound has good PARP1 inhibitory activity (IC50 is at a submicromole level), and compared with a PARP1 inhibitor olaparib on the market, the compound has better anti-myocardial hypertrophy activity, and can be used for preparing a medicine for treating myocardial hypertrophy. The potential of PARP1 as a target spot for treating cardiac hypertrophy is proved, and a potential therapeutic drug is provided for treating cardiac hypertrophy.

The invention discloses a heart state detection method and device, equipment and a medium. The method comprises the steps that target electrocardiogram data of a patient to be diagnosed are collected; according to the actual lead number corresponding to the target electrocardiogram data, selecting a target diagnosis neural network model matched with the actual lead number from a plurality of pre-trained standard diagnosis neural network models; the target electrocardiogram data are input into the target diagnosis neural network model, at least one target heart state label determined by the target diagnosis neural network model from a plurality of pre-calibrated heart state labels according to the target electrocardiogram data is obtained, and the at least one target heart state label is used for representing the actual heart state of the patient to be diagnosed. The neural network model is used for automatically analyzing the electrocardiogram data, the states of cardiac hypertrophy, expansion, enlargement and the like can be found in time through the electrocardiogram, heart abnormity can be found in time before symptoms such as heart failure, sudden death and arrhythmia are generated, and a patient can be diagnosed and treated in time.

The invention belongs to the technical field of biological medicines, and particularly discloses application of colchicine in preparation of a medicine for treating hypertrophic cardiomyopathy. Researches show that after colchicine is used for treatment, pathological changes such as cardiac fibrosis of hypertrophic cardiomyopathy are relieved. Further experimental results show that after colchicine treatment, the proportion of pro-inflammatory macrophages in the cardiac hypertrophy tissue is reduced, the IL-6 level is reduced, and it is prompted that the anti-inflammatory ability of colchicine can improve the microenvironment of the cardiac hypertrophy tissue, so that fibrosis is relieved, and the cardiac function is improved. The invention proves the clinical transformation potential of colchicine in the treatment of cardiac hypertrophy patients. If the medicine is applied clinically in the future, the risk of sudden cardiac death is expected to be reduced by relieving cardiac fibrosis, and a new treatment choice is provided for improving the prognosis of a hypertrophic cardiomyopathy patient.

The present application provides compositions and methods for treating cardiac hypertrophy. In one embodiment, the composition comprises an antisense oligonucleotide 10-50 nucleotides in length, wherein the antisense oligonucleotide is capable of forming a double-stranded structure with a target region downstream of a start codon of an upstream open reading frame (uORF) resided within an mRNA of GATA4, wherein the target region spans a double-stranded stem of a stem-loop structure downstream of the GATA4 uORF start codon

The present invention provides small molecule PAK1 (P21 Activated Kinase 1) and / or PAK2 (P21 Activated Kinase 2) activators and their use in the prevention and / or treatment of diseases or conditions responsive to PAK1 and / or PAK2 activity or diseases or conditions associated with PAK1 and / or PAK2 inactivity, e.g. cardiovascular diseases or conditions, including cardiac fibrosis, cardiac hypertrophy, cardiac arrhythmias, heart failure and ischaemia / reperfusion injury.

The invention provides application of a reagent for intervening circ-ZNF609 expression in preparation of a medicine for preventing and / or treating cardiac hypertrophy, and belongs to the technical field of biological medicine. The invention provides application of a reagent for intervening circ-ZNF609 expression in preparation of a medicine for preventing and / or treating cardiac hypertrophy. According to the invention, an adeno-associated virus delivery system is utilized to deliver a reagent targeting circ-ZNF609 into cardiac muscle tissues to interfere the expression of circ-ZNF609, so that cardiomyopathy hypertrophy can be inhibited, the cardiac contraction function can be improved, and pathological ventricular remodeling caused by pressure overload can be resisted at the same time. Therefore, the invention provides a new way for treating cardiac hypertrophy.

The invention provides application of sedum spectabile total flavonoids in preparation of a medicine for treating pathological cardiac hypertrophy. The sedum spectabile total flavone can inhibit abnormal hypertrophy of cardiac muscle cells, improve arrangement disorder and fibrosis of the cardiac muscle cells, relieve thickening of ventricular walls, improve the diastolic function, delay or reverse pathological cardiac hypertrophy and relieve mitochondrial dysfunction in cardiac muscle tissue with cardiac hypertrophy.

Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial hypertrophy, and belongs to the technical field of biology. Research results show that in a mouse cardiac hypertrophy model, compared with a control group mouse, heart weight / body weight, lung weight / body weight, cardiac muscle cell cross sectional area and fibrosis of a cardiac muscle cell specific Mboat7 gene overexpressed mouse are all remarkably reduced, and the cardiac systolic function is remarkably improved; the overexpressed Mboat7 gene can relieve isolated cell myocardial hypertrophy induced by angiotensin II. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissue of a cardiac hypertrophy mouse. The results show that the Mboat7 gene overexpression relieves the disease progress of the pathological cardiac hypertrophy, and the Mboat7 or the expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating the pathological cardiac hypertrophy.

The invention provides application of dragon's blood and active ingredients thereof in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. It is found for the first time that the dragon's blood can significantly improve the heart function of a heart failure model animal, reduce the level of a heart failure marker and relieve cardiac hypertrophy, cardiac pulmonary edema, myocarditis infiltration and fibrosis; core active components such as genistein and 3-hydroxycinnamic acid are screened and verified, wherein the genistein can reproduce the overall treatment effect of the dragon's blood. The invention also discloses that the core action mechanism of the composition is to promote macrophage VEGFC secretion, increase heart lymphatic vessel density and promote lymphatic vessel neogenesis, and a brand new natural drug candidate scheme and an intervention strategy are provided for heart failure treatment.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to clarify the effect of pan-connexin1 in the cardiac hypertrophy process caused by overload of pressure, the invention provides application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the invention, it is found for the first time that Pannexin1 is an effective target spot for treating myocardial hypertrophy caused by pressure overload, and an expression inhibitor for inhibiting Pannexin1 by targeting the target spot can be used for preparing drugs for treating myocardial hypertrophy caused by pressure overload. Therefore, the invention provides the application of the inhibitor targeting the Pannexin1 gene in preparation of the medicine for preventing or treating the myocardial fibrosis, and a new treatment mode is provided for treatment of the myocardial fibrosis.

The invention belongs to the technical field of biomedicine and biology, particularly relates to a medicine capable of treating diseases related to protein sedimentation, and particularly discloses a medicine for treating or improving diseases or symptoms related to protein sedimentation, the medicine contains Emc3 protein, and the amino acid sequence of the Emc3 protein is shown as SEQ ID No: 1; the nucleotide sequence of the Emc3 protein is as shown in SEQ ID No: 2. The Emc3 can be used as a target gene for screening and preparing drugs for improving cardiac protein sedimentation, cardiac myocardial cell hypertrophy, cardiac hypertrophy, cardiac failure and the like, reducing death caused by protein deposition and prolonging survival time.

The invention belongs to the technical field of biological medicines, and discloses a cardiac function enhancer and application thereof. The active ingredient of the cardiac function enhancer is polyunsaturated phosphatidyl ethanolamine or 3-denitrified adenosine. The polyunsaturated phosphatidyl ethanolamine can be directly used as a key lipid for enhancing the cardiac function. And 2, 3-denitrified adenosine competitively inhibits phosphatidyl ethanolamine methyltransferase to reduce the conversion of phosphatidyl ethanolamine to phosphatidylcholine, so that the level of endogenous polyunsaturated phosphatidyl ethanolamine is improved, and the same effect is indirectly achieved. The invention provides application of the active ingredients in preparation of medicines or nutritional supplements for treating heart diseases, preventing and inhibiting cardiac hypertrophy and improving heart functions.

Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods for their use as cardioprotectants are provided. Small molecule stimulators can be used to promote cardioprotection and repair and angiogenesis after myocardial infarction. The compounds can also be used to prevent cardiac hypertrophy and collagen deposition and improve function after myocardial infarction.

The invention provides an application of human circular RNA (Ribonucleic Acid) in preparation of a detection kit or a medicine for diagnosing pathological myocardial hypertrophy, and the human circular RNA comprises nucleic acid containing a sequence as shown in SEQ ID NO.1, or a bioactive functional fragment, a variant or a derivative of the nucleic acid containing the sequence as shown in SEQ ID NO.1. The invention also provides a derivative peptide generated by circular RNA translation. The invention also provides a kit for diagnosis or prognosis evaluation of pathological myocardial hypertrophy and a pharmaceutical composition for treatment or / and prevention of pathological myocardial hypertrophy. Compared with other types of markers, the human source circular RNA provided by the invention has stable and specific properties, has larger abundance in body fluid of a patient and more obvious change, and has the potential of becoming a novel diagnostic marker. The specific RNA interference adenovirus is prepared, and the expression efficiency is high; the virus genome cannot be integrated into the host cell genome, the controllability is good, and the safety is high.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a modified Zhenwu decoction traditional Chinese medicine compound and application thereof. The traditional Chinese medicine compound of the modified true Wu decoction is prepared from the following raw materials in parts by weight: 10 to 30 parts of radix aconiti lateralis praeparata slices, 6 to 18 parts of sun-dried ginseng, 10 to 30 parts of poria cocos, 8 to 24 parts of raw rhizoma atractylodis macrocephalae, 10 to 30 parts of radix paeoniae alba, 20 to 60 parts of pubescent holly root and 4 to 12 parts of rhodiola rosea. Clinical observation finds that the flavored Zhenwu decoction is an effective drug for resisting HFpEF, and can reverse cardiac hypertrophy of HFpEF mice, relieve pulmonary edema conditions, remarkably improve the diastolic function, improve HFpEF cardiac hypertrophy, improve cardiac diastolic dysfunction, improve myocardial injury and collagen deposition and improve myocardial cell mitochondrial injury.

The invention provides a hypertrophic obstructive cardiomyopathy ablation device and method, the device comprises an adjustable bending sheathing canal assembly, a mapping catheter, an ablation needle assembly and an ultrasonic assembly, the mapping catheter penetrates through the adjustable bending sheathing canal assembly, and can move to the far end of the adjustable bending sheathing canal assembly along the axial direction of the adjustable bending sheathing canal assembly to penetrate out; the mapping catheter is used for mapping the heart, and the ablation needle assembly is used for conducting chemical ablation on the hypertrophy part of the ventricular septum of the right ventricle. The ultrasonic assembly can move to the far end of the adjustable bending sheath tube assembly to penetrate out, and the ultrasonic assembly is used for monitoring the position of the ablation needle assembly. According to the hypertrophy obstructive cardiomyopathy ablation device, the ultrasonic assembly, the ablation needle assembly and the mapping catheter are integrated, under the real-time image guidance of the ultrasonic assembly, the ablation needle assembly is controlled to conduct chemical ablation on the cardiac hypertrophy part, and the accuracy of the ablation position and the ablation depth are ensured; on the premise of safe ablation, alcohol ablation is given, so that myocardial necrosis in the deep layer of the ventricular septum is realized, and obstruction is relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of limonin in preparation of a medicine for improving the left ventricular diastolic function. The CAS number of the limonin is 180-71-8, the molecular formula of the limonin is C26H30O8, and the limonin in the medicine is an effective component. Tests find that after ejection fraction reserved heart failure (HFpEF) model group mice are subjected to limonin high, medium and low dose administration, compared with the model group without administration, the weight of the heart and lung of the mice is remarkably reduced, left ventricular diastolic dysfunction and centripetal cardiac hypertrophy of the mice can be remarkably improved, and the curative effect of the mice is improved. Compared with the positive drug empagliflozin, the drug effect indexes have no obvious difference. Besides, HE and Masson staining finds that compared with control group mice, obvious myocardial interstitial fibrosis occurs in the model group mice, and myocardial fibrosis can be obviously improved after limonin is high, medium and low and empagliflozin is administrated.

The invention discloses an application of Gitogenin (Gitogenin, GIT) in preparation of a medicine for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. According to the application disclosed by the invention, the prevention or treatment of the hypertrophic cardiomyopathy by the Gitogenin is proposed for the first time, and experiments find that the in-vitro treatment of the Gitogenin can obviously inhibit the phenotype of myocardial cell hypertrophy; gitogenin is applied to gavage treatment on a mouse with hereditary hypertrophic cardiomyopathy caused by gene mutation, and the Gitogenin is found to obviously relieve pathological cardiac hypertrophy of the mouse and improve the cardiac function. The Gitogenin can be used for preparing the medicine for resisting the hereditary hypertrophic cardiomyopathy, and a new way and means are provided for treating the hypertrophic cardiomyopathy; in addition, the Gitogenin is clearly reported to be a main natural steroid component separated from a whole plant of a plant Tribulus longipetaus (a caltrop plant), the biological safety of the Gitogenin to organisms is high, and the Gitogenin has a good application prospect in clinic.

The invention discloses an application of circular RNA circRftn1 in treatment of cardiac hypertrophy, the circRftn1 is the circular RNA found for the first time, circBase ID of the circRftn1 is nucirc0004641, the research finds that the circRftn1 is highly expressed in cardiac muscle tissues of a cardiac hypertrophy cell model and an animal model, the circRftn1 is highly expressed in peripheral blood and cardiac muscle tissues of a cardiac hypertrophy patient, and the circRftn1 is highly expressed in the cardiac muscle tissues of the cardiac hypertrophy cell model and the animal model. The siRNA for inhibiting circRftn1 expression can reduce the myocardial cell volume of a myocardial hypertrophy cell model and an animal model; it is found that the circRftn1 / mumiR-1192 network plays an important role in activating an NF-B p65 signal channel by regulating and controlling TRIM25 / TRIM41 molecular expression, and it is likely that the circRftn1 is inhibited to improve the action mechanism of cardiac hypertrophy.

The invention relates to application of an Art3 gene in preparation of a medicine for treating heart failure and myocardial remodeling. The Art3 gene is a myocardial cell maturation marker, is specifically expressed in normal myocardial cells, and is down-regulated under pathological conditions of heart failure, myocardial remodeling and the like. Knockout of the Art3 gene can cause decompensation of myocardial hypertrophy, and an animal with the gene knockout can be used as a myocardial hypertrophy and heart failure model. By activating the downstream target ITGA7 protein of the Art3 gene, myocardial hypertrophy caused by down-regulation of the Art3 gene can be rescued. These findings provide a new target for the treatment of myocardial diseases.